Target intelligence / Profile preview

Central descending serotonergic pain-modulating pathway

Molecular classification
G protein-coupled receptor, Transporter, Ion channel
01

Overview

The central descending serotonergic pain-modulating pathway is a fundamental neural circuit responsible for the top-down regulation of nociceptive processing (Ossipov et al., 2014, Nature Reviews Neuroscience). Originating primarily from the nucleus raphe magnus within the rostral ventromedial medulla (RVM), these serotonergic neurons project to the spinal cord's dorsal horn to modulate incoming pain signals (Bannister & Dickenson, 2016, Curr Opin Support Palliat Care). The pathway is unique in its bidirectional nature; it can either inhibit pain (antinociception) via 5-HT1 receptors or facilitate pain (pro-nociception) via 5-HT2 or 5-HT3 receptors (StatPearls, 2023, Physiology, Pain). In chronic pain conditions like fibromyalgia or neuropathic pain, there is often a shift toward descending facilitation or a loss of descending inhibition (Nature Reviews Neuroscience, 2014). Many analgesic drugs, such as Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Tricyclic Antidepressants (TCAs), exert their effects by increasing serotonin levels in the spinal synapse to reinforce these inhibitory controls (Marks et al., 2009, Current Neuropharmacology). Consequently, this pathway serves as a major focus for pharmacological and neuromodulatory therapies aimed at restoring normal pain processing.

Other names
Descending serotonergic pathwayBulbospinal serotonergic systemRVM-spinal serotonergic projectionEndogenous pain modulation system
02

Mechanism of action

Potentiation of descending inhibitory signals through the inhibition of serotonin reuptake, increasing synaptic serotonin availability in the spinal dorsal horn to activate inhibitory receptors.

03

Biological functions

Nociception modulationPain inhibitionPain facilitationSignal transduction
04

Disease associations

Chronic painNeuropathic painFibromyalgiaMigraineDepression
05

Safety considerations

Serotonin syndromeSexual dysfunctionNauseaRisk of suicidal ideationWithdrawal syndrome
06

Interacting drugs

Duloxetine

5 more in the full profile.

07

Biomarkers

Conditioned Pain Modulation (CPM)Quantitative Sensory Testing (QST)Cerebrospinal fluid 5-Hydroxyindoleacetic acid (5-HIAA) levels

Beyond the preview

Go deeper on Central descending serotonergic pain-modulating pathway.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Central descending serotonergic pain-modulating pathway.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call